Cognitive impairment in nondemented Parkinson's disease

Movement Disorders

Volumn 26, Issue 14, 2011, Pages 2483-2495

  Barone, Paolo ^a,b   Aarsland, Dag ^c   Burn, David ^d   Emre, Murat ^e   Kulisevsky, Jaime ^f   Weintraub, Daniel ^g  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ISTANBUL UNIVERSITY   (Turkey)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Assessment; CIND PD; Mild cognitive impairment; Parkinson's disease; Symptoms

Indexed keywords

AMANTADINE; ATOMOXETINE;

CLINICAL FEATURE; COGNITIVE DEFECT; CRITERION VARIABLE; DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

DEMENTIA; HUMANS; INCIDENCE; MILD COGNITIVE IMPAIRMENT; NOOTROPIC AGENTS; PARKINSON DISEASE; PREVALENCE; RISK FACTORS;

EID: 83555179205     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23919     Document Type: Review

References (129)

1. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain. 2004; 127: 550-560.
2. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005; 65: 1239-1245.
3. Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep. 2011; 11: 371- 378.
4. Mamikonyan E, Moberg PJ, Siderowf A, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord. 2009; 15: 226-231.
5. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001; 56: 730-736.
6. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009; 132: 2958-2969.
7. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006; 12: 35-41.
8. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004; 52: 784-788.
9. Klepac N, Trkulja V, Relja M, Babic T. Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol. 2008; 15: 128-133.
10. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007; 78: 36-42.
11. Carbon M, Marie RM. Functional imaging of cognition in Parkinson's disease. Curr Opin Neurol. 2003; 16: 475-480.
12. De Leonibus E, Manago F, Giordani F, et al. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology. 2009; 34: 729-738.
13. Meyer PM, Strecker K, Kendziorra K, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009; 66: 866-877.
14. Aarsland D, Beyer MK, Kurz MW. Dementia in Parkinson's disease. Curr Opin Neurol. 2008; 21: 676-682.
15. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997; 349: 1793-1796.
16. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56: 303-308.
17. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58: 1985-1992.
18. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256: 183-194.
19. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009; 72: 1121-1126.
20. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007; 22: 1272-1277.
21. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord. 2006; 21: 1343-1349.
22. Green J, McDonald WM, Vitek JL, et al. Cognitive impairments in advanced PD without dementia. Neurology. 2002; 59: 1320-1324.
23. Bronnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP. Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology. 2011; 25: 114-124.
24. Cronin-Golomb A, Braun AE. Visuospatial dysfunction and problem solving in Parkinson's disease. Neuropsychology. 1997; 11: 44-52.
25. Dujardin K, Degreef JF, Rogelet P, Defebvre L, Destee A. Impairment of the supervisory attentional system in early untreated patients with Parkinson's disease. J Neurol. 1999; 246: 783-788.
26. Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia. 2003; 41: 645-654.
27. Siegert RJ, Weatherall M, Taylor KD, Abernethy DA. A meta-analysis of performance on simple span and more complex working memory tasks in Parkinson's disease. Neuropsychology. 2008; 22: 450-461.
28. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol. 2004; 17: 195-200.
29. Osman M, Wilkinson L, Beigi M, Castaneda CS, Jahanshahi M. Patients with Parkinson's disease learn to control complex systems via procedural as well as non-procedural learning. Neuropsychologia. 2008; 46: 2355-2363.
30. Wilkinson L, Jahanshahi M. The striatum and probabilistic implicit sequence learning. Brain Res. 2007; 1137: 117-130.
31. Wilkinson L, Khan Z, Jahanshahi M. The role of the basal ganglia and its cortical connections in sequence learning: evidence from implicit and explicit sequence learning in Parkinson's disease. Neuropsychologia. 2009; 47: 2564-2573.
32. Pillon B, Deweer B, Michon A, Malapani C, Agid Y, Dubois B. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology. 1994; 44: 1264-1270.
33. Whittington CJ, Podd J, Kan MM. Recognition memory impairment in Parkinson's disease: power and meta-analyses. Neuropsychology. 2000; 14: 233-246.
34. Whittington CJ, Podd J, Stewart-Williams S. Memory deficits in Parkinson's disease. J Clin Exp Neuropsychol. 2006; 28: 738-754.
35. Carbon M, Ma Y, Barnes A, et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage. 2004; 21: 1497-1507.
36. Stern Y, Langston JW. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 1985; 35: 1506-1509.
37. Stern Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology. 1990; 40: 261-264.
38. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991; 114: 2095-2122.
39. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord. 2006; 21: 223-229.
40. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008; 70: 1470- 1477.
41. Junque C, Ramirez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord. 2005; 20: 540-544.
42. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov Disord. 2003; 18: 784-790.
43. Ibarretxe-Bilbao N, Tolosa E, Junque C, Marti MJ. MRI and cognitive impairment in Parkinson's disease. Mov Disord. 2009; 24( Suppl 2): S748-S753.
44. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry. 2007; 78: 254-259.
45. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol. 2007; 14: 750-756.
46. Bronnick K, Emre M, Tekin S, Haugen SB, Aarsland D. Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2011; 26: 824-829.
47. Santangelo G, Trojano L, Vitale C, et al. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Mov Disord. 2007; 22: 2418-2425.
48. Llebaria G, Pagonabarraga J, Martinez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord. 2010; 25: 2785-2791.
49. Dagher A, Owen AM, Boecker H, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain. 2001; 124: 1020-1032.
50. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain. 2002; 125: 584-594.
51. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol. 2002; 51: 156-164.
52. Dagher A, Nagano-Saito A. Functional and anatomical magnetic resonance imaging in Parkinson's disease. Mol Imaging Biol. 2007; 9: 234-242.
53. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 2000; 100: 285-290.
54. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009; 23: 295-297.
55. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81: 1080-1086.
56. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta> 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010; 75: 1055-1061.
57. Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord. 2003; 15: 126-131.
58. Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009; 73: 1469-1477.
59. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010; 75: 1062-1069.
60. Reid W, Hely M, Morris JG, et al. A longitudinal study of Parkinson's disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci. 1996; 2: 327-333.
61. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004; 61: 1906-1911.
62. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord. 2008; 23: 1889-1896.
63. Nazem S, Siderowf AD, Duda JE, et al. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009; 57: 304-308.
64. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol. 2006; 5: 578-588.
65. Muslimovic D, Schmand B, Speelman JD, de Haan RJ. Course of cognitive decline in Parkinson's disease: a meta-analysis. J Int Neuropsychol Soc. 2007; 13: 920-932.
66. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord. 2002; 17: 1221-1226.
67. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord. 2007; 23: 281-288.
68. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010; 81: 650-657.
69. Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord. 2009; 24: 2391-2397.
70. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992; 55: 377-382.
71. Mavandadi S, Nazem S, Ten Have TR, et al. Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. Am J Geriatr Psychiatry. 2009; 17: 986-995.
72. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol. 2009; 256: 632-638.
73. Starkstein SE, Preziosi TJ, Berthier ML, Bolduc PL, Mayberg HS, Robinson RG. Depression and cognitive impairment in Parkinson's disease. Brain. 1989; 112: 1141-1153.
74. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry. 2005; 20: 668-673.
75. Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord. 2009; 24: 899-905.
76. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol. 2009; 66: 39-47.
77. Amboni M, Cozzolino A, Longo K, Picillo M, Barone P. Freezing of gait and executive functions in patients with Parkinson's disease. Mov Disord. 2008; 23: 395-400.
78. Amboni M, Picollo M, Cozzolino A. Neuropsychiatric disturbances in parkinsonian patients with and without freezing of gait. Mov Disord. 2009; 24: S233.
79. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord. 2009; 24: 1103-1110.
80. Aarsland D, Litvan I, Salmon D, et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003; 74: 1215-1220.
81. Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing. 2005; 34: 268-273.
82. Brown GG, Rahill AA, Gorell JM, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol. 1999; 12: 180-188.
83. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 1993; 269: 2386-2391.
84. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000; 55: 1621-1626.
85. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
86. Harvey PD, Ferris SH, Cummings JL, et al. Evaluation of dementia rating scales in Parkinson's disease dementia. Am J Alzheimers Dis Other Demen. 2010; 25: 142-148.
87. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing. 1999; 28: 39-43.
88. Hofer SM, Piccinin AM, Hershey D. Analysis of structure and discriminative power of the Mattis Dementia Rating Scale. J Clin Psychol. 1996; 52: 395-409.
89. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson's disease. Neurology. 2009; 73: 1738-1745.
90. Kalbe E, Calabrese P, Kohn N, et al. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord. 2008; 14: 93-101.
91. Mahieux FMM, Boller F, Fermanian J, Guillard G. Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. Behav Neurolog. 1995; 8: 15-22.
92. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology. 2003; 61: 1222-1228.
93. Mattis S. Dementia Rating Scale: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1988.
94. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53: 695-699.
95. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord. 2008; 23: 998-1005.
96. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol. 2008; 255: 255-264.
97. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141: 1356-1364.
98. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Goddard R. CAMDEX: the Cambridge Examination for Mental Disorders. Cambridge, UK: Cambridge University Press; 1988.
99. Vitaliano PP, Breen AR, Russo J, Albert M, Vitiello MV, Prinz PN. The clinical utility of the dementia rating scale for assessing Alzheimer patients. J Chronic Dis. 1984; 37: 743-753.
100. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010; 75: 1717-1725.
101. Martinez-Martin P, Prieto-Jurczynska C, Frades-Payo B. [Psychometric attributes of the Parkinson's Disease-Cognitive Rating Scale. An independent validation study]. Rev Neurol. 2009; 49: 393-398.
102. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007; 22: 2314-2324.
103. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007; 22: 1689-1707.
104. Martin RC, Okonkwo OC, Hill J, et al. Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia. Mov Disord. 2008; 23: 1867-1874.
105. Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord. 2010; 25: 1170-1176.
106. Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry. 2008; 79: 1386-1391.
107. Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000; 15: 613-626.
108. Brusa L, Tiraboschi P, Koch G, et al. Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm. 2005; 112: 231-237.
109. Gotham AM, Brown RG, Marsden CD. Levodopa treatment may benefit or impair "frontal" function in Parkinson's disease. Lancet. 1986; 2: 970-971.
110. Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain. 1996; 119: 2121-2132.
111. Pascual-Sedano B, Kulisevsky J, Barbanoj M, et al. Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc. 2008; 14: 832-841.
112. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006; 30: 1-23.
113. Jahanshahi M, Wilkinson L, Gahir H, Dharminda A, Lagnado DA. Medication impairs probabilistic classification learning in Parkinson's disease. Neuropsychologia. 2010; 48: 1096-1103.
114. Foltynie T, Lewis SG, Goldberg TE, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol. 2005; 252: 833-838.
115. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009; 80: 18-23.
116. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord. 2006; 21: 1375-1379.
117. Linazasoro G, Lasa A, Van BN. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study. Clin Neuropharmacol. 2005; 28: 176-178.
118. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord. 2009; 24: 277-282.
119. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004; 351: 2509-2518.
120. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010; 75: 448-455.
121. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008; 300: 1027-1037.
122. Tanaka K, Quadros ACJr, Santos RF, Stella F, Gobbi LT, Gobbi S. Benefits of physical exercise on executive functions in older people with Parkinson's disease. Brain Cogn. 2009; 69: 435-441.
123. Eggermont L, Scherder E. Chronic exercise in brain disease. In: McMorris T, Tomporowski P, Audiffren M, eds. Exercise and Cognitive Function. Hoboken, NJ: Wiley-Blackwell; 2009: 285-306.
124. Scheltens P. Moving forward with nutrition in Alzheimer's disease. Eur J Neurol. 2009; 16( Suppl 1): 19-22.
125. Wilkinson L, Beigi M, Lagnado DA, Jahanshahi M. Deep brain stimulation of the subthalamic nucleus selectively improves learning of weakly associated cue combinations during probabilistic classification learning in Parkinson's disease. Neuropsychology. 2011; 25: 286-294.
126. Page D, Jahanshahi M. Deep brain stimulation of the subthalamic nucleus improves set shifting but does not affect dual task performance in Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng. 2007; 15: 198-206.
127. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005; 128: 2240-2249.
128. Jahanshahi M, Rowe J, Saleem T, et al. Striatal contribution to cognition: working memory and executive function in Parkinson's disease before and after unilateral posteroventral pallidotomy. J Cogn Neurosci. 2002; 14: 298-310.
129. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology. 2007; 68: 1726-1729.